Fentanyl is a synthetic opioid with short-acting analgesic activity after intravenous or
subcutaneous administration. The low molecular weight, high potency and lipid solubility of …

BACKGROUND Some patients with cancer pain may develop uncontrolled adverse effects,
including generalized myoclonus, delirium, nausea and emesis, or severe sedation before …

Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …

Transdermal delivery allows continuous systemic application of opioids through the intact
skin. This review analyses the pharmacokinetic properties of transdermal opioid …

Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused
by malignancy and non-malignant conditions when administered according to the …

As was the case in the era before us, in the new millennium we will continue to see an
abundance of patients experiencing cancer-related pain for different reasons. Although …

Fentanyl has been incorporated into a transdermal therapeutic system (TTS) containing a
rate-limiting membrane that provides constant release of the opioid. TTS fentanyl provides …

Transdermal fentanyl was released in Germany in 1995. From October 1996 to February
1998 transdermal treatment was documented for 1005 patients (506 men and 499 women …

This study compares subcutaneous (sc) morphine and fentanyl with respect to pain control
and side effects using a 6-day randomized, double-blind, cross-over design. Results were …

Constipation is a common symptom in cancer patients, especially in those who are receiving
opioid analgesics for pain. Although several articles have recently examined constipation …